Amyloid Beta Peptide and S1P Liposomal Formulation for Alzheimer's
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Alzheimer's disease treatments using amyloid beta peptide vaccines often induce inflammatory reactions, limiting their therapeutic efficacy and safety.
Innovation Solution
Administering amyloid beta peptide 42 in combination with Sphingosine-1-phosphate (S1P) in a liposomal formulation to induce a beneficial immune response while preventing inflammation and promoting neuronal repair and regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If amyloid beta peptide vaccines are administered to treat Alzheimer's disease, then immune response is induced to reduce amyloid deposits, but inflammatory reactions occur in the brain
Solution Approach 1:
The patent introduces Sphingosine-1-phosphate (S1P) as an intermediary substance that modulates the immune response. S1P acts as a mediator between the amyloid beta peptide vaccine and the host immune system, promoting beneficial immune responses while suppressing harmful inflammatory reactions. This intermediary approach allows the therapeutic benefits of amyloid beta vaccination to be achieved without the severe inflammatory side effects observed in previous treatments.
Solution Approach 2:
The patent changes the pharmacological parameters of the treatment by combining amyloid beta peptide with S1P at specific ratios and concentrations. This parameter modification transforms the nature of the immune response from purely inflammatory to a balanced response that includes both anti-amyloid immunity and anti-inflammatory effects, thereby resolving the contradiction between therapeutic efficacy and harmful inflammation.
2Productivity
If high doses of amyloid beta peptide are administered to reduce amyloid deposits, then therapeutic effect is enhanced, but inflammatory reactions and toxicity increase
Solution Approach 1:
S1P serves as a protective intermediary that enables the administration of higher doses of amyloid beta peptide without proportionally increasing toxicity. The intermediary S1P buffers the harmful effects of high-dose amyloid beta, allowing enhanced amyloid deposit reduction while maintaining safety through its anti-inflammatory and neuroprotective properties.
Solution Approach 2:
The patent creates a composite therapeutic formulation combining amyloid beta peptide with S1P. This composite material exhibits synergistic effects where the combination produces greater therapeutic benefit than either component alone, while the composite nature distributes and mitigates the harmful effects, enabling higher productivity without proportional increase in toxicity.
3Reliability
If amyloid beta peptide is used to induce immune response, then amyloid deposits are reduced, but neuronal damage and apoptosis occur
Solution Approach 1:
S1P acts as a neuroprotective intermediary that shields neurons from damage while allowing the immune response to proceed effectively against amyloid deposits. The intermediary S1P maintains the necessary immune activation for amyloid reduction while simultaneously preventing neuronal apoptosis and damage, thus resolving the contradiction between immune response induction and neuronal protection.
Solution Approach 2:
The patent converts the potentially harmful effect of immune activation (which causes neuronal damage) into a beneficial outcome by using S1P to redirect the immune response. The same immune activation that could cause neuronal harm is transformed, through S1P modulation, into a protective anti-amyloid response that spares neurons, effectively converting a harmful process into a beneficial one.
Data Source
AI summary
The invention provides compositions and methods for treatment of Alzheimer's disease. Such methods entail administering agents that induce a beneficial immune and therapeutic response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In certain preferred embodiments of such methods, a preferred agent is amyloid beta peptide in combination with Sphingosine-1-phosphate, preferably delivered in certain embodiments in a liposomal formulation.